1
|
Moya-Gil A, Martínez-Gómez MA, Porta-Oltra B, Merino-Sanjuán M, Climente-Martí M. Physico-Chemical Stability of Admixtures of Vinflunine Used in Clinical Practice. J Pharm Sci 2021; 110:2687-2693. [PMID: 33610565 DOI: 10.1016/j.xphs.2021.02.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 01/28/2021] [Accepted: 02/10/2021] [Indexed: 11/17/2022]
Abstract
Procedure of administration of vinflunine is complex and consists of an Y-site injection with fluid at different speeds. Dose is diluted with 100 mL of 0.9% sodium chloride or 5% glucose and infused with half of the 500 mL bag of the fluid over 20 min; after that, the remaining fluid is administered at 300 mL/h. In this study, chemical stability and physical compatibility of vinflunine diluted with in 500 mL of both fluids were evaluated to simplify the administration procedure (infusion of mixture on 20 min followed by 250 mL of fluid at 300 mL/h). Physical compatibility and chemical stability were evaluated at two temperatures and protected from and exposed to light. Physical compatibility was evaluated by visual inspection, gravimetric control and measure of pH. A chromatographic method was developed to evaluate chemical stability. The dilution of vinflunine with 500 mL of fluid to final concentrations of 0.75 and 1.54 mg/mL is viable at doses used in clinical practice since admixtures are stable for 2 days at room temperature and at least 7 days under refrigeration. These results extend the expiration date of mixtures of vinflunine administered by the usual procedure and confirm the viability of the proposed procedure since administration is simplified and stability of vinflunine is guaranteed.
Collapse
Affiliation(s)
- Ana Moya-Gil
- Department of Pharmacy, Universitary Doctor Peset Hospital, Valencia, Spain
| | - María Amparo Martínez-Gómez
- Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana, (FISABIO), Valencia, Spain.
| | - Begoña Porta-Oltra
- Department of Pharmacy, Universitary Doctor Peset Hospital, Valencia, Spain
| | - Matilde Merino-Sanjuán
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, Pharmacy Faculty, University of Valencia, Valencia, Spain
| | | |
Collapse
|
2
|
Guichard N, Guillarme D, Bonnabry P, Fleury-Souverain S. Antineoplastic drugs and their analysis: a state of the art review. Analyst 2017; 142:2273-2321. [DOI: 10.1039/c7an00367f] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
We provide an overview of the analytical methods available for the quantification of antineoplastic drugs in pharmaceutical formulations, biological and environmental samples.
Collapse
Affiliation(s)
- Nicolas Guichard
- Pharmacy
- Geneva University Hospitals (HUG)
- Geneva
- Switzerland
- School of Pharmaceutical Sciences
| | - Davy Guillarme
- School of Pharmaceutical Sciences
- University of Geneva
- University of Lausanne
- Geneva
- Switzerland
| | - Pascal Bonnabry
- Pharmacy
- Geneva University Hospitals (HUG)
- Geneva
- Switzerland
- School of Pharmaceutical Sciences
| | | |
Collapse
|
3
|
Li P, Wang X, Li J, Meng ZY, Li SC, Li ZJ, Lu YY, Ren H, Lou YQ, Lu C, Dou GF, Zhang GL. Quantitative and qualitative analysis of the novel antitumor 1,3,4-oxadiazole derivative (GLB) and its metabolites using HPLC-UV and UPLC-QTOF-MS. Sci Rep 2015; 5:11906. [PMID: 26148672 PMCID: PMC4493701 DOI: 10.1038/srep11906] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Accepted: 06/03/2015] [Indexed: 12/30/2022] Open
Abstract
Fructose-based 3-acetyl-2,3-dihydro-1,3,4-oxadiazole (GLB) is a novel antitumor agent and belongs to glycosylated spiro-heterocyclic oxadiazole scaffold derivative. This research first reported a simple, specific, sensitive and stable high performance liquid chromatography-ultraviolet detector (HPLC-UV) method for the quantitative determination of GLB in plasma. In this method, the chromatographic separation was achieved with a reversed phase C18 column. The calibration curve for GLB was linear at 300 nm. The lower limit of quantification was 10 ng/mL. The precision, accuracy and stability of the method were validated adequately. This method was successfully applied to the pharmacokinetic study in rats for detection of GLB after oral administration. Moreover, the structures of parent compound GLB and its two major metabolites M1 and M2 were identified in plasma using an ultra performance liquid chromatography-electrospray ionization-quadrupole-time of flight- mass spectrometry (UPLC-ESI-QTOF-MS) method. Our results indicated that the di-hydroxylation (M1) and hydroxylation (M2) of GLB are the major metabolites. In conclusion, the present study provided valuable information on an analytical method for the determination of GLB and its metabolites in rats, can be used to support further developing of this antitumor agent.
Collapse
Affiliation(s)
- Pu Li
- Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100191, PR. China
| | - Xin Wang
- Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100191, PR. China
| | - Jian Li
- Laboratory of Hematological Pharmacology, Beijing Institute of Transfusion Medicine, Beijing 100850, PR China
| | - Zhi-Yun Meng
- Laboratory of Hematological Pharmacology, Beijing Institute of Transfusion Medicine, Beijing 100850, PR China
| | - Shu-Chun Li
- Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, PR. China
| | - Zhong-Jun Li
- Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, PR. China
| | - Ying-Yuan Lu
- Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100191, PR. China
| | - Hong Ren
- Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100191, PR. China
| | - Ya-Qing Lou
- Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100191, PR. China
| | - Chuang Lu
- Millennium Pharmaceuticals-Takeda, Cambridge, Massachusetts, USA
| | - Gui-Fang Dou
- Laboratory of Hematological Pharmacology, Beijing Institute of Transfusion Medicine, Beijing 100850, PR China
| | - Guo-Liang Zhang
- Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100191, PR. China
| |
Collapse
|
4
|
A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer. Cancer Chemother Pharmacol 2014; 73:903-10. [DOI: 10.1007/s00280-014-2420-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Accepted: 02/19/2014] [Indexed: 10/25/2022]
|
5
|
Delord JP, Ravaud A, Bennouna J, Fumoleau P, Favrel S, Pinel MC, Ferré P, Saliba F. Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. Invest New Drugs 2012; 31:724-33. [DOI: 10.1007/s10637-012-9878-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Accepted: 09/04/2012] [Indexed: 10/27/2022]
|
6
|
Paridaens R, Rixe O, Pinel MC, Wildiers H, Zorza G, Ferré P, Roche H. A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2012; 70:503-11. [DOI: 10.1007/s00280-012-1930-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2012] [Accepted: 07/14/2012] [Indexed: 10/28/2022]
|
7
|
Delord JP, Bennouna J, Mourey L, Bougaret J, Brandely-Talbot M, Ferré P. Vinflunine Oral Pharmacokinetics and Absolute Bioavailability of Soft and Hard Gelatin Capsules. Clin Pharmacokinet 2012; 51:357-64. [DOI: 10.2165/11599300-000000000-00000] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
9
|
Campone M, Isambert N, Bourbouloux E, Roché H, Bonneterre J, Milano G, Fumoleau P. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 2011; 69:871-9. [DOI: 10.1007/s00280-011-1767-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2011] [Accepted: 10/13/2011] [Indexed: 10/16/2022]
|